Hirobriz Breezhaler

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
08-09-2021
Tabia za bidhaa Tabia za bidhaa (SPC)
08-09-2021

Viambatanisho vya kazi:

indacaterol maleate

Inapatikana kutoka:

Novartis Europharm Limited

ATC kanuni:

R03AC18

INN (Jina la Kimataifa):

indacaterol

Kundi la matibabu:

Drugs for obstructive airway diseases,

Eneo la matibabu:

Pulmonary Disease, Chronic Obstructive

Matibabu dalili:

Hirobriz Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.

Bidhaa muhtasari:

Revision: 18

Idhini hali ya:

Authorised

Idhini ya tarehe:

2009-11-30

Taarifa za kipeperushi

                                56
B. PACKAGE LEAFLET
57
PACKAGE LEAFLET: INFORMATION FOR THE USER
HIROBRIZ BREEZHALER 150 MICROGRAM INHALATION POWDER, HARD CAPSULES
HIROBRIZ BREEZHALER 300 MICROGRAM INHALATION POWDER, HARD CAPSULES
indacaterol
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1.
What Hirobriz Breezhaler is and what it is used for
2.
What you need to know before you use Hirobriz Breezhaler
3.
How to use Hirobriz Breezhaler
4.
Possible side effects
5.
How to store Hirobriz Breezhaler
6.
Contents of the pack and other information
1.
WHAT HIROBRIZ BREEZHALER IS AND WHAT IT IS USED FOR
WHAT HIROBRIZ BREEZHALER IS
Hirobriz Breezhaler contains the active substance indacaterol which
belongs to a group of medicines
called bronchodilators. When you inhale it, it relaxes the muscles in
the walls of the small air passages
in the lungs. This helps open up the airways, making it easier to get
air in and out.
WHAT HIROBRIZ BREEZHALER IS USED FOR
Hirobriz Breezhaler is used to make breathing easier for adult
patients who have breathing difficulties
due to a lung disease called chronic obstructive pulmonary disease
(COPD). In COPD the muscles
around the airways tighten. This makes breathing difficult. This
medicine relaxes these muscles in the
lungs, making it easier for air to get in and out of the lungs.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE HIROBRIZ BREEZHALER
DO NOT USE HIROBRIZ BREEZHALER
-
if you are allergic to indacaterol or any of the other ingredients of
this medicine (listed in
section 6).
WARNINGS AND PRECAUTIONS
Talk to your
                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Hirobriz Breezhaler 150 microgram inhalation powder, hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each capsule contains indacaterol maleate equivalent to 150 microgram
indacaterol.
The delivered dose leaving the mouthpiece of the inhaler is
indacaterol maleate equivalent to
120 microgram indacaterol.
Excipient with known effect
Each capsule contains 24.8 mg lactose.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Inhalation powder, hard capsule
Transparent (uncoloured) capsules containing a white powder, with
“IDL 150” printed in black above
a black bar and company logo (
) printed in black below the black bar.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Hirobriz Breezhaler is indicated for maintenance bronchodilator
treatment of airflow obstruction in
adult patients with chronic obstructive pulmonary disease (COPD).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The recommended dose is the inhalation of the content of one 150
microgram capsule once a day,
using the Hirobriz Breezhaler inhaler. The dose should only be
increased on medical advice.
The inhalation of the content of one 300 microgram capsule once a day,
using the Hirobriz Breezhaler
inhaler has been shown to provide additional clinical benefit with
regard to breathlessness, particularly
for patients with severe COPD. The maximum dose is 300 microgram once
daily.
Hirobriz Breezhaler should be administered at the same time of the day
each day.
If a dose is missed the next dose should be taken at the usual time
the next day.
_Special populations _
_Elderly population_
Maximum plasma concentration and overall systemic exposure increase
with age but no dose
adjustment is required in elderly patients.
_Hepatic impairment _
No dose adjustment is required for patients with mild and moderate
hepatic impairment. There are no
data available for use of Hirobriz Breezhaler in patients with severe
hepatic impairment.
3
_Renal impair
                                
                                Soma hati kamili
                                
                            

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 08-09-2021
Tabia za bidhaa Tabia za bidhaa Kibulgaria 08-09-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 12-10-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 08-09-2021
Tabia za bidhaa Tabia za bidhaa Kihispania 08-09-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 12-10-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 08-09-2021
Tabia za bidhaa Tabia za bidhaa Kicheki 08-09-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 12-10-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 08-09-2021
Tabia za bidhaa Tabia za bidhaa Kidenmaki 08-09-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 12-10-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 08-09-2021
Tabia za bidhaa Tabia za bidhaa Kijerumani 08-09-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 12-10-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 08-09-2021
Tabia za bidhaa Tabia za bidhaa Kiestonia 08-09-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 12-10-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 08-09-2021
Tabia za bidhaa Tabia za bidhaa Kigiriki 08-09-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 12-10-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 08-09-2021
Tabia za bidhaa Tabia za bidhaa Kifaransa 08-09-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 12-10-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 08-09-2021
Tabia za bidhaa Tabia za bidhaa Kiitaliano 08-09-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 12-10-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 08-09-2021
Tabia za bidhaa Tabia za bidhaa Kilatvia 08-09-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 12-10-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 08-09-2021
Tabia za bidhaa Tabia za bidhaa Kilithuania 08-09-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 12-10-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 08-09-2021
Tabia za bidhaa Tabia za bidhaa Kihungari 08-09-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 12-10-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 08-09-2021
Tabia za bidhaa Tabia za bidhaa Kimalta 08-09-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 12-10-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 08-09-2021
Tabia za bidhaa Tabia za bidhaa Kiholanzi 08-09-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 12-10-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 08-09-2021
Tabia za bidhaa Tabia za bidhaa Kipolandi 08-09-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 12-10-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 08-09-2021
Tabia za bidhaa Tabia za bidhaa Kireno 08-09-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 12-10-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 08-09-2021
Tabia za bidhaa Tabia za bidhaa Kiromania 08-09-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 12-10-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 08-09-2021
Tabia za bidhaa Tabia za bidhaa Kislovakia 08-09-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 12-10-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 08-09-2021
Tabia za bidhaa Tabia za bidhaa Kislovenia 08-09-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 12-10-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 08-09-2021
Tabia za bidhaa Tabia za bidhaa Kifinlandi 08-09-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 12-10-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 08-09-2021
Tabia za bidhaa Tabia za bidhaa Kiswidi 08-09-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 12-10-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 08-09-2021
Tabia za bidhaa Tabia za bidhaa Kinorwe 08-09-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 08-09-2021
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 08-09-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 08-09-2021
Tabia za bidhaa Tabia za bidhaa Kroeshia 08-09-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 12-10-2017

Tafuta arifu zinazohusiana na bidhaa hii